BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27653892)

  • 1. Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
    Wang Y; Cai H; Zhou G; Zhang Z; Liu X
    J Neurol Sci; 2016 Oct; 369():216-219. PubMed ID: 27653892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
    Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
    J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
    Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
    Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
    Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
    CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
    Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
    J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
    Zhang J; Zhang J; Sun H; Ming T; Liu X; Cong Y; Li F; Li Z
    Int J Clin Pharmacol Ther; 2017 Oct; 55(10):789-797. PubMed ID: 28766499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
    Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
    Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
    Jia DM; Chen ZB; Zhang MJ; Yang WJ; Jin JL; Xia YQ; Zhang CL; Shao Y; Chen C; Xu Y
    Stroke; 2013 Jun; 44(6):1717-9. PubMed ID: 23640828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    Wang Y; Zhao X; Lin J; Li H; Johnston SC; Lin Y; Pan Y; Liu L; Wang D; Wang C; Meng X; Xu J; Wang Y;
    JAMA; 2016 Jul; 316(1):70-8. PubMed ID: 27348249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
    Yi X; Lin J; Wang Y; Zhou Q; Wang C; Cheng W; Chi L
    J Atheroscler Thromb; 2016 Oct; 23(10):1188-1200. PubMed ID: 26961113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
    Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
    Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia.
    Zhu WY; Zhao T; Xiong XY; Li J; Wang L; Zhou Y; Gong ZL; Cheng SY; Liu Y; Shuai J; Yang QW
    Sci Rep; 2016 May; 6():25478. PubMed ID: 27137706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
    Choi IJ; Koh YS; Park MW; Her SH; Choi YS; Park CS; Park HJ; Kim PJ; Chung WS; Kim HS; Shin JG; Seung KB; Chang K
    Medicine (Baltimore); 2016 Jun; 95(26):e4049. PubMed ID: 27368038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.
    Lin J; Mo Y; Cai D; Mao D; Fu H; Wei D
    Ann Palliat Med; 2021 Dec; 10(12):12171-12180. PubMed ID: 35016407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Yi X; Zhou Q; Wang C; Lin J; Chai Z
    J Neurol; 2018 Oct; 265(10):2396-2403. PubMed ID: 30128710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
    Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
    Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.